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Hepatocellular carcinoma (HCC), or liver 
cancer, is the third leading cause of cancer 
deaths worldwide [World Health Organization 
(WHO) 2008], with roughly 550,000–
600,000 new HCC cases globally each year 
(Ferlay et al. 2004). Aflatoxin exposure in food 
is a significant risk factor for HCC (Wild and 
Gong 2010). Aflatoxins are primarily produced 
by the food-borne fungi Aspergillus flavus and 
Aspergillus parasiticus, which colonize a variety 
of food commodities, including maize, oilseeds, 
spices, groundnuts, and tree nuts in tropical and 
subtropical regions of the world. Additionally, 
when animals that are intended for dairy pro-
duction consume aflatoxin-  contaminated feed, 
a metabolite, aflatoxin M1, is excreted in the 
milk (Strosnider et al. 2006).
Aflatoxins are a group of approximately 
20 related fungal metabolites. The four major 
aflatoxins are known as B1, B2, G1, and 
G2. Aflatoxins B2 and G2 are the dihydro-
  derivatives of the parent compounds B1 and G1 
(Pitt and Tomaska 2001). Aflatoxin B1 (AFB1) 
is the most potent (in some species) naturally 
occurring chemical liver carcinogen known. 
Naturally occurring mixes of aflatoxins have 
been classified as a Group 1 human carcinogen 
by the International Agency for Research on 
Cancer (IARC) and has demonstrated carci-
nogenicity in many animal species, including 
some rodents, nonhuman primates, and fish 
[International Programme on Chemical Safety 
(IPCS)/WHO 1998)]. Specific P450 enzymes 
in the liver metabolize aflatoxin into a reactive 
oxygen species (aflatoxin-8,9-epoxide), which 
may then bind to proteins and cause acute 
toxicity (aflatoxicosis) or to DNA to cause 
lesions that over time increase the risk of HCC 
(Groopman et al. 2008).
HCC as a result of chronic aflatoxin expo-
sure has been well documented, presenting 
most often in persons with chronic hepatitis B 
virus (HBV) infection (Wild and Gong 2010). 
The risk of liver cancer in individuals exposed 
to chronic HBV infection and aflatoxin is up 
to 30 times greater than the risk in individu-
als exposed to aflatoxin only (Groopman et al. 
2008). These two HCC risk factors—aflatoxin 
and HBV—are prevalent in poor nations 
worldwide. Within these nations, there is often 
a significant urban–rural difference in aflatoxin 
exposure and HBV prevalence, with both these 
risk factors typically affecting rural populations 
more strongly (Plymoth et al. 2009).
Aflatoxin also appears to have a synergistic 
effect on hepatitis C virus (HCV)-induced liver 
cancer (Kirk et al. 2006; Kuang et al. 2005; 
Wild and Montesano 2009), although the 
quantitative relationship is not as well estab-
lished as that for aflatoxin and HBV in induc-
ing HCC. Other important causative factors in 
the development of HCC, in addition to HBV 
or HCV infection and aflatoxin exposure, are 
the genetic characteristics of the virus, alco-
hol consumption, and the age and sex of the 
infected person (Kirk et al. 2006).
The IPCS/WHO undertook an aflatox-
in–HCC risk assessment in 1998 to estimate 
the impact on population cancer incidence 
by moving from a hypothetical total aflatoxin 
standard of 20 ng/g to 10 ng/g (Henry et al. 
1999; IPCS/WHO 1998). Assuming that all 
food containing higher levels of aflatoxin than 
the standard was discarded and that enough 
maize and nuts remained to preserve consump-
tion patterns, IPCS/WHO determined that 
HCC incidence would decrease by about 300 
cases per year per billion people, if the stricter 
aflatoxin standard were followed in nations 
with HBV prevalence of 25%. However, in 
nations where HBV preva  lence was 1%, the 
stricter aflatoxin standard would save only two 
HCC cases per year per billion people. This 
assessment associated HCC risk with particu-
lar doses of aflatoxin; however, these doses do 
not correspond with actual exposure in differ-
ent parts of the world, and the two hypotheti-
cal values for HBV prevalence, 1% and 25%, 
were not intended to represent actual HBV 
prevalence worldwide.
Currently, > 55 billion people worldwide 
suffer from uncontrolled exposure to afla-
toxin (Strosnider et al. 2006). What remains 
unknown is how many cases of liver cancer 
can be attributed to this aflatoxin exposure 
worldwide. Indeed, the Aflatoxin Workgroup 
(Strosnider et al. 2006), convened by the 
Centers for Disease Control and Prevention 
and WHO, identified four issues that war-
rant immediate attention: quantifying human 
health impacts and burden of disease due to 
aflatoxin exposure, compiling an inventory 
of ongoing intervention strategies, evaluating 
their efficacy, and disseminating the results.
Addressing this first issue is the aim of our 
study. We compiled available information 
on aflatoxin exposure and HBV prevalence 
from multiple nations in a quantitative cancer 
risk assessment, to estimate the number of 
HCC cases attributable to aflatoxin world-
wide per year. Shephard (2008) estimated 
population risk for aflatoxin-induced HCC 
in select African nations; we expand this 
to include the rest of the world. We briefly 
describe interventions that can either reduce 
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aflatoxin directly in food or reduce adverse 
health effects caused by aflatoxin.
Materials and Methods
To perform a quantitative cancer risk assess-
ment for aflatoxin-related HCC, we ana-
lyzed extensive data sets by nation or world 
region: food consumption patterns (of maize 
and peanuts), aflatoxin levels in maize and 
peanuts, HBV prevalence, and population 
size. Risk assessment is the process of esti-
mating the magnitude and the probability 
of a harmful effect to individuals or popula-
tions from certain agents or activities. Four 
steps are involved in estimation of the risk: 
hazard identification, dose–response analysis, 
exposure assessment, and risk characterization 
(National Research Council 1983).
Hazard identification. Hazard iden-
tification is the process of determining 
whether exposure to an agent can increase 
the incidence of a particular health condi-
tion. Aflatoxin exposure is associated with 
an increase in incidence of HCC in humans 
and sensitive animal species (Groopman et al. 
2008); in fact, IARC has classified AFB1 
naturally occurring mixes of aflatoxins as a 
Group 1 carcinogen (IARC 2002).
Dose–response analysis. This second risk 
assessment step involves characterizing the 
relationship between the dose of an agent—in 
this case, aflatoxin—and incidence of HCC. 
Because of the synergistic impact of aflatoxin 
and HBV in inducing HCC, the assessment 
must be done separately for populations with 
and without chronic HBV infection. Although 
chronic HCV infection may also have syner-
gistic effects with aflatoxin in inducing HCC, 
we did not include this effect in the analyses 
for three reasons: a) there is much less overlap 
worldwide between aflatoxin and HCV expo-
sures in general; b) chronic HCV infection 
usually occurs later in life, whereas chronic 
HBV infection occurs much earlier, thus the 
time of overlapped exposure is less significant 
for aflatoxin and HCV (Groopman J, per-
sonal communication); and c) much less is 
known about the quantitative relationship of 
aflatoxin and HCV in inducing HCC.
For cancer risk assessment, it is tradition-
ally assumed that there is no threshold of 
exposure to a carcinogen below which there 
is no observable adverse effect (National 
Research Council 2008). Cancer potency fac-
tors are estimated from the slope of the dose–
response relationship, which is assumed to be 
linear, between doses of the carcinogen and 
cancer incidence in a population. The IPSC/
WHO aflatoxin risk assessment selected two 
different cancer potency factors for aflatoxin: 
0.01 cases/100,000/year/nanogram/kilogram 
body weight per day aflatoxin exposure for 
individuals without chronic HBV infection, 
and 0.30 corresponding cases for individuals 
with chronic HBV infection. This was based 
on one cohort study that estimated can-
cer potency in individuals positive for the 
HBV surface antigen (HBsAg; a biomarker 
of chronic HBV infection) and in HBsAg-
negative individuals (Yeh et al. 1989), as well 
as other human studies that assessed cancer 
potency among either HBsAg-positive or 
HBsAg-negative individuals. We used these 
same potency factors for this risk assessment. 
Because only one of the studies (Yeh et al. 
1989) specifically assessed cancer potency in 
both cohorts, considerable uncertainty may 
be associated with these potency factors. 
However, several epidemiological studies con-
firm that aflatoxin’s cancer potency is about 
30 times greater among HBV-positive than 
among HBV-negative individuals (Kirk et al. 
2005, Ok et al. 2007; Qian et al. 1994).
Exposure assessment. Exposure assess-
ment involves estimating the intensity, fre-
quency, and duration of human exposures 
to a toxic agent. Specifically, we sought to 
determine how individuals’ exposure to afla-
toxin increases their risk of HCC. Aflatoxin 
exposure is a function not only of aflatoxin 
concentrations in maize and nuts but also 
of how much of these foodstuffs individuals 
consume in different parts of the world.
Aflatoxin exposure assessment has evolved 
significantly over the past two decades, largely 
due to the characterization of biomarkers for 
both aflatoxin exposure and effect (Groopman 
et al. 2005, 2008). Before these biomarkers, 
the primary way to estimate aflatoxin expo-
sure was to observe how much maize and nuts 
people consumed on average and to meas-
ure or assume aflatoxin levels in these foods. 
By meas  uring biomarkers such as aflatoxin– 
albumin adducts in serum or aflatoxin-N7-
guanine in urine, it is possible to improve 
estimations of aflatoxin exposure and how 
much has been biotransformed to increase 
cancer risk (Groopman et al. 2008).
Because aflatoxin biomarker data worldwide 
are limited, we collected data on estimated HBV 
prevalence in these countries and on maize and 
nut consumption patterns in different world 
regions and estimated average aflatoxin expo-
sure or contamination levels in the maize and 
nuts in different world regions. Where aflatoxin 
exposure data were not already estimated, we 
used food consumption patterns and aflatoxin 
contamination levels to estimate exposure. The 
studies estimating HBV prevalence were based 
on HBsAg detection among males and among 
females in both urban and rural settings across all 
age groups. Data on maize and peanut consump-
tion in different world regions are adapted from 
the WHO Global Environment Monitoring 
System (GEMS)/Food Consumption Cluster 
Diets database (WHO 2006). We estimated 
aflatoxin exposure data in different nations from 
multiple sources through literature searches.
Risk characterization. This final step of 
risk assessment integrates dose–response and 
exposure data to describe the overall nature 
and magnitude of risk. For our study, this final 
step consisted of quantifying, across the globe, 
the burden of aflatoxin-related liver cancer. 
For each nation, we estimated total number of 
individuals with or without chronic HBV by 
multiplying prevalence by population size. To 
estimate aflatoxin-induced HCC rates within 
these two populations (with and without 
chronic HBV infection), we multiplied the 
corresponding cancer potency factor by afla-
toxin exposure estimates. Then we multiplied 
these values by each nation’s HBV-positive 
and HBV-negative population sizes to derive 
total number of aflatoxin-induced HCC cases 
in each nation. We summed across all world 
regions to arrive at an estimate for global bur-
den of aflatoxin-induced HCC.
Results
Table 1 lists the prevalence of chronic HBV 
infection by world region, as measured 
by HBsAg in different parts of the world. 
Although these different estimates involve 
uncertainty and variability, all data are from 
literature published in or after 2000, to ensure 
that the HBV prevalence estimates are as cur-
rent and as relevant as possible. Countries are 
grouped by WHO designated regions (WHO 
2005): Africa, North America and Latin 
America, Eastern Mediterranean, Southeast 
Asia, Western Pacific, and Europe. Some 
regions were divided into subgroups because 
of significantly varied aflatoxin exposure and 
HBV prevalence within the region.
Table 2 provides calculations of maize and 
peanut consumption in select countries of the 
world. The GEMS/Food Consumption Cluster 
Diets database divides countries of the world 
into 13 groups based on diets. For each group 
cluster, the GEMS food consumption database 
has estimated the amount of cereals, nuts, and 
oilseeds consumed. We thus estimated aver-
age maize and nut consumption by individual 
country. There are limitations to these data 
because of the clustering into 13 groups (with 
potentially wide ranges among nations within 
a group), as well as variability in data quality 
regarding diet and aflatoxin exposure estimates.
We estimated (based on Tables 1 and 2) 
or found in the literature the average afla-
toxin exposure in different world regions and 
then calculated the estimated incidence of 
aflatoxin-induced HCC, with and without 
the synergistic impact with HBV, in the cor-
responding populations of each nation and 
world region (Table 3). Within each WHO-
designated region, we found aflatoxin expo-
sures in the most populous nations. The “in 
general” rows in Table 3 represent a small 
proportion of each region: nations in which 
aflatoxin data were not available, or very Liu and Wu
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small nations. For these, we assumed a range 
for aflatoxin exposure that incorporated the 
ranges of the nations within the region for 
which we found aflatoxin data.
These data provide the necessary infor-
mation to calculate the total estimated cases 
of aflatoxin-induced HCC cases annually, 
worldwide. Table 4 lists populations for each 
relevant nation and world region. Accounting 
for chronic HBV infection prevalence as 
shown in Table 1, and the risk estimates for 
HBV-positive versus HBV-negative indi-
viduals in Table 3, the numbers of cases of 
aflatoxin-induced HCC can be estimated in 
each world region. These are then summed 
to produce a global estimate of the number 
of annual aflatoxin-induced HCC cases. Our 
estimate is that anywhere from 25,200 to 
155,000 annual HCC cases worldwide may 
be attributable to aflatoxin exposure.
Figure 1 illustrates the distribution of 
HCC cases attributable to aflatoxin globally. 
The categories denote WHO world regions. 
Sub-Saharan Africa is the most important 
region for HCC cases attributable to aflatoxin; 
Southeast Asia and China (in the Western 
Pacific region) are also key regions where 
aflatoxin-related HCC is an important risk. 
Relatively fewer cases occur in the Americas, 
Eastern Mediterranean, and Europe. Although 
Australia and New Zealand are grouped with 
the Western Pacific region, these nations also 
have low aflatoxin-induced HCC incidence. It 
is notable that in Mexico, where HBV preva-
lence is relatively low but aflatoxin contamina-
tion in food is relatively high, aflatoxin appears 
to be a significant risk factor for HCC among 
those without HBV (an estimated 152–924 
HCC cases per year per 100,000 people).
Discussion
Aflatoxin contamination in food is a serious 
global health problem, particularly in devel-
oping countries. Although it has been known 
for several decades that aflatoxin causes liver 
cancer in humans, the exact burden of afla-
toxin-related HCC worldwide was unknown. 
This study represents a first step in attempt-
ing to estimate that burden. We find that at 
its lower estimate, aflatoxin plays a role in 
about 4.6% of total annual HCC cases; at 
its upper estimate, aflatoxin may play a role 
roughly 28.2% of all HCC cases worldwide. 
This large range stems from the considerable 
uncertainty and variability in data on cancer 
potency factors, HBV prevalence, aflatoxin 
exposure, and other risk factors in different 
world regions. The most heavily afflicted parts 
of the world are sub-Saharan Africa, Southeast 
Asia, and China.
As indicated in Table 3, populations in 
developing countries in tropical and subtropi-
cal areas are nearly ubiquitously exposed to 
moderate to high levels of aflatoxin. Aflatoxin 
is a controllable risk factor in food, yet the 
parts of the world in which the risk is par-
ticularly high have limited resources to imple-
ment most aflatoxin control strategies. Much 
Table 2. Maize and peanut consumption in select 
countries.
WHO region/country
Maizea  
(g/person/day)
Peanutb  
(g/person/day)
Africa
Democratic Republic 
of Congo
57 52
Ethiopia 83 13
The Gambia 57 52
Kenya 248 11
Mozambique 248 11
Nigeria 57 52
South Africa 248 11
Tanzania 248 11
Zimbabwe 248 11
North America and Latin America
Canada 86 17
United States 86 17
Argentina 86 17
Brazil 63 2
Mexico 300 5
Eastern Mediterranean
Egypt 136 5
Iran 32 2
Pakistan 35 18
Sudan 57 52
Southeast Asia
India 35 18
Indonesia 35 18
Thailand 35 18
Western Pacific
Australia 86 17
China 35 18
Malaysia 35 18
Philippines 59 2
Republic of Korea 59 2
Europe
Eastern Europe 32 2–10
Southern Europe 148 7
Western Europe 33 10
Data are adapted from GEMS/Food Consumption Cluster 
Diets database (WHO 2006).
aIncluding maize, flour and germ.bIncluding groundnuts 
in shell and shelled.
Table 1. Estimates of HBV prevalence in select countries based on HBsAg seroprevalence. 
WHO region/country References
Chronic HBV  
prevalence (%)
Africa
Democratic Republic of Congo Batina et al. 2007; Mbendi et al. 2001 6–10 
Ethiopia Abebe et al. 2003; Shimelis et al. 2008 6–7 
The Gambia Kirk et al. 2004; Vall et al. 1990 15–20 
Kenya Kiire 1996; Tuei 1994 11–15 
Mozambique Cunha et al. 2007 4.5–10.6 
Nigeria Fasola et al. 2008 13.2 
South Africa Custer et al. 2004; Kiire 1996 3.3–10.4 
Tanzania Hasegawa et al. 2006; Matee et al. 2006; Miller et al. 1998 5–9 
Zimbabwe Kiire 1996; Tswana et al. 1996 10–15 
Others Kiire 1996; Matee et al. 2006; Tayou et al. 2009 9–20 
North America and Latin America
Canada Minuk and Uhanova 2001; Zhang et al. 2001 1–2 
United States CDC 2009; Cohen et al. 2008; WHO 2005 0.3–2 
Argentina Paraná and Almeida 2005; Torres 1996 0.8–1.1 
Brazil Paraná and Almeida 2005; Torres 1996 2.1–3.4 
Mexico Roman et al. 2009 < 0.3 
Others Paraná and Almeida 2005; Torres 1996 0.5–3 
Eastern Mediterranean
Egypt Ismail et al. 2009; Lehman and Wilson 2009; Youssef et al. 2009 2.2–10.1 
Iran Kafi-Abad et al. 2009a, 2009b 0.41–0.56
Pakistan Butt and Amin 2008; Khattak et al. 2002 3.3 
Sudan Elsheikh et al. 2007 6–26
Others Abou et al. 2009; Batayneh and Bdour 2002; Ameen et al. 2005; 
WHO 2005
0.65–10 
Southeast Asia
India Behal et al. 2008; Tandon et al. 1996 2.4– 4.7 
Indonesia Hong et al. 2001; Merican et al. 2000; van Hattum et al. 2003 2.5–5
Thailand Tanprasert and Somjitta 1993 4.6–8 
Others Alam et al. 2007; Ali et al. 2009; Jafri et al. 2006; WHO 2005 2–7
Western Pacific
Australia WHO 2007 < 1 
China Merican et al. 2000; WHO 2007 8–10 
Malaysia Merican et al. 2000; WHO 2007 5 
Philippines Domingo 1997; Lansang 1996; WHO 2007 5–16 
Korea Song et al. 2009; WHO 2007 4–5 
Others Gust 1996; Merican et al. 2000; Nakata et al. 1994 1–10 
Europe
Eastern Europe Magdzik 2000; Resuli et al. 2009 2–7 
Southern Europe Da Villa 1998; Gogos et al. 2003; WHO 2005 2–7 
Western Europe Hahné et al. 2004; WHO 2005; Jilg et al. 2001 0.5–1 
CDC, Centers for Disease Control and Prevention.Global burden of aflatoxin-induced liver cancer
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agricultural land in Africa and Asia lies in 
climatic regions favorable for A. flavus and 
A. parasiticus proliferation. Suboptimal field 
practices and poor drying/storage condi-
tions make crops vulnerable to fungal infec-
tion and aflatoxin accumulation. Maize and 
groundnuts, the two crops most conducive 
to Aspergillus infection, are staples in many 
African and Asian diets. Because the very poor 
in these regions cannot afford much food vari-
ety, these staples make up a significant portion 
of their diets, increasing aflatoxin exposure.
Even within the same nation, aflatoxin-
  induced HCC risk can vary significantly among 
different populations, hence the large national 
ranges for risk shown in Table 4. Rural popula-
tions generally have higher levels of aflatoxin 
exposure than do urban dwellers in developing 
countries (Wild and Hall 2000), because urban 
populations typically consume more diversified 
diets than do rural dwellers and may have food 
that is better controlled for contaminants. In 
addition, there is a strong seasonal variation 
in aflatoxin exposure that correlates with food 
availability (Gnonlonfin et al. 2008; Tajkarimi 
et al. 2007). Moreover, HBV prevalence is gen-
erally higher in rural areas than in urban ones, 
and higher among males than among females in 
most places (Plymoth et al. 2009). We present 
our collected data of HBsAg seroprevalence as a 
range for countries or populations (Table 1), to 
account for these variations.
Although many nations that suffer from 
both high aflatoxin exposures and high HBV 
prevalence have nominally established maxi-
mum allowable aflatoxin standards in food, 
there is little if any enforcement of these 
standards in many rural areas. Indeed, the 
food in subsistence farming and local food 
markets is rarely formally inspected. Strict 
aflatoxin standards can even lead to large eco-
nomic losses for poor food-exporting nations 
when trading with other nations (Wu 2004). 
Subsistence farmers and local food traders 
sometimes have the luxury of discarding 
Table 3. Estimated HCC incidence attributable to aflatoxin, by WHO region.
WHO region/country 
Aflatoxin exposure 
(ng/kg body weight/daya)
Estimated annual HCC (per 100,000)
Reference HBsAg-negative  HBsAg-positive
Africa
Democratic Republic of Congo Manjula et al. 2009b 0.07–27 0.0007–0.27 0.02–8.10
Ethiopia Ayalew et al. 2006b 1.4–36 0.01–0.36 0.42–10.8
The Gambia Hall and Wild 1994; Shephard 2008 4–115 0.04–1.15 1.20–34.5
Kenya Hall and Wild 1994; Shephard 2008 3.5–133 0.04–1.33 1.05–39.9
Mozambique Hall and Wild 1994 39–180 0.39–1.80 11.7–54.0
Nigeria Bandyopadhyay et al. 2007; Bankole and Mabekoje 2004b 139–227 1.39–2.27 41.7–68.1
South Africa Hall and Wild 1994; Shephard 2003 0–17  0–0.17 0–5.10
Tanzania Manjula et al. 2009b 0.02–50 0.0002–0.50 0.06–15.0
Zimbabwe IPCS/WHO 1998 17.5–42.5 0.18–0.43 5.25–12.8
In generalc Hall and Wild 1994; Shephard 2008 10–180 0.10–1.80 3.0–54.0
North America
Canada Kuiper-Goodman 1995 0.2–0.4d 0.002–0.004 0.06–0.12
United States IPCS/WHO 1998 0.26 0.003 0.08
In generalc 0.26–1 0.003–0.01 0.08–0.3
Latin America
Argentina Etcheverry et al. 1999; Solovey et al. 1999b 0–4 0–0.04 0–1.20
Brazil IARC 2002; Midio et al. 2001; Oliveira et al. 2009; Vargas et al. 2001b 0.23–50 0.002–0.50 0.07–15.0
Mexico García and Heredia 2006; Guzmán-de-Peña and Peña-Cabriales 2005; 
Torres et al. 1995b
14–85 0.14–0.85 4.20–25.5
In generalc 20–50 0.20–0.50 6.0–15.0
Eastern Mediterranean
Egypt Anwar et al. 2008b 7–57 0.07–0.57 2.1–17.1
Iran Hadiani et al. 2009; Mazaheri 2009b 5–8.5 0.05–0.09 1.50–2.55
Pakistan Munir et al. 1989b 7–50 0.07–0.50 2.10–15.0
Sudan Omer et al. 1998 19–186 0.19–1.86 5.70–55.8
In generalc 10–80 0.10–0.80 3.00–24.0
Southeast Asia
India Vasanthi 1998 4–100 0.04–1.00 1.20–30.0
Indonesia Ali et al. 1998; IARC 2002; Noviandi et al. 2001b 9–122 0.09–1.22 2.7–36.6
Thailand Hall and Wild 1994; Lipigorngoson et al. 2003b 53–73 0.53–0.73 15.9–21.9
In generalc 30–100 0.30–1.00 9.00–30.0
Western Pacific
Australia NHMRC 1992; Pitt and Tomaska 2001 0.15–0.18 ~0.002 ~0.05
China Li et al. 2001; Qian et al. 1994; Wang and Liu 2007; Wang et al. 2001b 17–37 0.17–0.37 5.10–11.1
Malaysia Ali et al. 1999; IARC 2002b 15–140 0.15–1.4 4.5–42
Philippines Ali et al. 1999; IARC 2002; Sales and Yoshizawa 2005b 44–54 0.44–0.54 13.2–16.2
Republic of Korea Ok et al. 2007; Park et al. 2004 1.2–6 0.01–0.06 0.36–1.80
In generalc 15–50 (except Australia 
and New Zealand)
0.15–0.50 4.5–15.0
Europe
Eastern Europe Malir et al. 2006e 3.5–4 0.04 ~1.20
Southern Europe Battilani et al. 2008; Giray et al. 2007f 0–4 0–0.04 0–1.20
Western Europe IARC 2002 0.3–1.3 0.003–0.01 0.09–0.39
In generalc 0–4 0–0.04 0–1.2
NHMRC, National Health and Medical Research Council. 
aAssuming 60 kg body weight per individual. bAflatoxin exposure was estimated by multiplying aflatoxin concentrations in staple foods by consumption rates of those foods (WHO 2006). 
cAflatoxin exposure estimates and consequent HCC cases for all other countries classified in the same WHO region. dAflatoxin exposure of 1–2 ng/kg body weight/day was measured 
in children’s diets; here we assume the adult daily aflatoxin intake is 20% that of children. eAverage daily aflatoxin intake was estimated based on AFB1 contamination levels in Czech 
maize, multiplied by average daily maize consumption in Eastern Europe. fAverage daily aflatoxin intake was estimated based on AFB1 contamination levels in maize of North Italy and 
Turkey, multiplied by average daily maize consumption in Southern Europe.Liu and Wu
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obviously moldy maize and groundnuts. But 
in drought seasons, oftentimes people have 
no choice but to eat moldy food or starve 
(Williams 2008).
Multiple public health interventions 
exist to control the burden of aflatoxin in 
the body and to prevent HCC. These inter-
ventions, described in greater detail in Wu 
and Khlangwiset (2010), can be grouped 
into three categories: agricultural, dietary, 
and clinical. Agricultural interventions can 
be applied either in the field (preharvest) or 
in storage and transportation (postharvest) 
to reduce aflatoxin levels in key crops. They 
can thus be considered primary interventions. 
Dietary and clinical interventions can be con-
sidered secondary interventions. They cannot 
reduce actual aflatoxin levels in food, but they 
can reduce aflatoxin-related illness, either by 
reducing aflatoxin’s bioavailability in the body 
or by ameliorating aflatoxin-induced damage. 
Because aflatoxin-mediated mutations may 
precede HCC by several years, the effects of 
reducing aflatoxin exposure on HCC inci-
dence may take time to become apparent 
(Szymañska et al. 2009).
One highly effective clinical interven-
tion to reduce aflatoxin-related HCC is vac-
cination against HBV. Vaccinating children 
against HBV has, over the past 30 years, sig-
nificantly decreased HBV infection in sev-
eral regions, including Europe (Bonanni et al. 
2003; Williams et al. 1996), Taiwan (Chen 
et al. 1996), and Thailand (Jutavijittum 
et al. 2005). This vaccine will, over time, 
lessen the global carcinogenic impact of 
aflatoxin, because removing the synergistic 
impact between HBV and aflatoxin expo-
sure would significantly reduce HCC risk. 
However, there are currently roughly 360 
million chronic HBV carriers worldwide, and 
HBV vaccination is still not incorporated into 
many national immunization programs (Wild 
and Hall 2000). Thus, adopting measures to 
reduce dietary exposure to aflatoxins is crucial 
for public health.
Our study highlights the significant role 
of aflatoxin in contributing to global liver 
cancer burden. Most cases occur in sub-
  Saharan Africa, Southeast Asia, and China, 
where populations suffer from both high 
HBV prevalence and largely uncontrolled 
exposure to aflatoxin in the food. Not all risk 
factors for HCC, including synergistic roles 
between aflatoxin and other carcinogens, are 
clearly understood; hence, these estimates for 
number of global aflatoxin-induced HCC 
cases have a large range. Although it is impos-
sible to completely eliminate aflatoxin in food 
worldwide, it is possible to significantly reduce 
levels and dramatically reduce liver cancer 
incidence worldwide. The challenge remains 
to deliver these interventions to places of the 
world where they are most needed.
Table 4. Estimated annual global burden of HCC cases attributable to aflatoxin exposure in HBsAg-
positive and HBsAg-negative populations.
Annual HCC cases 
WHO region/country Population (millions)a HBsAg-negative HBsAg-positive
Africa
Democratic Republic of Congo 68 1–173 1–551
Ethiopia 85 11–288 21–643
The Gambia 1.7 1–17 3–117
Kenya 38 11–450 44–2,270
Mozambique 21 73–361 111–1,200
Nigeria 149 1,800–2,940 8,200–13,400
South Africa 48 0–79 0–255
Tanzania 41 1–195 1–554
Zimbabwe 13 19–50 68–249
Total region 755 2,150–9,300 9,230–50,600
North America
Canada 33 1 1
United States 300 8 1–5
Total region 333 9 2–5
Latin America
Argentina 40 0–16 0–5
Brazil 190 4–930 3–969
Mexico 109 152–924 14–83
Total region 562 589–2,980 84–2,060
Eastern Mediterranean
Egypt 81 51–452 37–1400
Iran 66 33–56 4–9
Pakistan 172 116–832 119–851
Sudan 41 58–717 140–5,950
Total region 569 446–3,720 341–13,200
Southeast Asia
India 1,150 438–11,200 331–16,200
Indonesia 237 203–2,820 160–4,340
Thailand 63 307–439 461–1,100
Total region ~1,734 1,740–17,300 1,460–27,600
Western Pacific region
Australia 21 0–1 0–1
China 1,300 1,990–4,430 5,300–14,400
Korea 50 5–29 6–45
Malaysia 28 40–372 63–588
Philippines 90 333–462 594–2,330
Total region ~1,740 2,710–6,510 6,310–21,200
Europe
Eastern Europe 290 94–114 61–244
Southern Europe 144 0–56 0–121
Western Europe 183 5–24 1–7
Total region 617 99–184 62–372
Total (world) 6,280 7,700–40,000 17,500–115,000
Total annual HCC cases attributable 
to aflatoxin worldwide
25,200–155,000
aData from Central Intelligence Agency 2009.
Figure 1. Distribution of HCC cases attributable to aflatoxin in different regions of the world.
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